New clinical trial studies immunotherapy and chemotherapy in Kaposi sarcoma herpesvirus-associated lymphomas


Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are rare and aggressive cancers of the blood. They often occur in patients whose immune systems have been compromised by HIV. The Center for Cancer Research (CCR) has launched a study of a treatment that combines immunotherapy with chemotherapy for patients with KSHV-associated lymphomas. Thomas Uldrick, M.D., of the HIV/AIDS Malignancy Branch is leading the trial to test the safety and side effects of this combination treatment and to see if the study drugs can increase survival. View more information about this trial here.

Summary Posted: 04/2017